IC-MPGN clinical trials at UCSF

1 research study open to eligible people

IC-MPGN is an immune-related disease that damages tiny kidney filters. UCSF is conducting a placebo-controlled, randomized trial testing the drug iptacopan. The trial is double-blind and gathers data on safety and kidney measures.

Showing trials for

  • Iptacopan in Participants With IC-MPGN

    open to eligible people ages 12-60

    This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

    San Francisco, California and other locations

Our lead scientists for IC-MPGN research studies include .

Last updated: